Sat, Mar 7, 2015, 12:11 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • chris_cs16 chris_cs16 May 7, 2013 11:46 AM Flag

    Roth Analyst Says to Buy - $18 price target

    Shares of Synta Pharma. (NASDAQ: SNTA) are lower on Tuesday, a moved tied to the resignation of the company's R&D President Sumant Ramachandra. The resignation was revealed in SEC filings late on Monday, and no reason was given, leaving investors guessing.

    Commenting, Roth Capital analyst Joseph Pantginis said the timing may be viewed as negative by investors ahead of Galaxy-1 data presentation at the ASCO meeting in June. However, he doesn't think the resignation is cause for concern. In fact, he sees today's sell-off as a buying opportunity, as he expects positive data at ASCO and plenty of positive news flow in the days ahead.

    Roth Capital has a Buy rating on Synta Pharma. with a price target of $18.00

2.53-0.14(-5.24%)Mar 6 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.